Overview
- Multiple law firms announced securities class actions and investigations targeting ImmunityBio with a lead‑plaintiff deadline of May 26, 2026.
- The filed case in the Central District of California, Douglas v. ImmunityBio, covers investors who bought shares from January 19, 2026 through March 24, 2026.
- The FDA warned that a TV ad and a podcast about Anktiva were false or misleading, saying they implied the drug could cure or prevent all cancer and left out key limits of its approved use.
- Following reports of the FDA letter on March 24, 2026, ImmunityBio’s stock fell about 21% and lost nearly $2 billion in market value.
- The company said it removed the flagged materials, began executive training, tightened promotional reviews with outside counsel, and later reported about $44.2 million in preliminary Q1 2026 product revenue along with broader country authorizations for Anktiva.